Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

Autor: Fichtner ML; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America.; Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America., Hoarty MD; UCB Pharma, Cambridge, Massachusetts, United States of America., Vadysirisack DD; UCB Pharma, Cambridge, Massachusetts, United States of America., Munro-Sheldon B; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America., Nowak RJ; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America., O'Connor KC; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America.; Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2022 Mar 15; Vol. 17 (3), pp. e0264489. Date of Electronic Publication: 2022 Mar 15 (Print Publication: 2022).
DOI: 10.1371/journal.pone.0264489
Abstrakt: Acetylcholine receptor (AChR) autoantibodies, found in patients with autoimmune myasthenia gravis (MG), can directly contribute to disease pathology through activation of the classical complement pathway. Activation of the complement pathway in autoimmune diseases can lead to a secondary complement deficiency resulting in reduced complement activity, due to consumption, during episodes of disease activity. It is not clear whether complement activity in MG patients associates with measurements of disease activity or the titer of circulating pathogenic AChR autoantibodies. To explore such associations, as a means to identify a candidate biomarker, we measured complement activity in AChR MG samples (N = 51) using a CH50 hemolysis assay, then tested associations between these values and both clinical status and AChR autoantibody titer. The majority of the study subjects (88.2%) had complement activity within the range defined by healthy controls, while six patients (11.8%) showed reduced activity. No significant association between complement activity and disease status or AChR autoantibody titer was observed.
Competing Interests: The authors have read the journal’s policy and have the following competing interests: KCO has received research support from Ra Pharma, now a part of UCB Pharma. DDV and MDH are paid employees of UCB Pharma. RJN has received research support from UCB Pharma and served as consultant/advisor for UCB Pharma. The study did not receive funding via any of the authors’ salaries. These competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje